Market Closed -
Nasdaq
04:00:00 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
405.7
USD
|
+1.12%
|
|
+4.18%
|
+32.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,010
|
4,952
|
7,782
|
6,589
|
9,405
|
12,402
|
-
|
-
|
Enterprise Value (EV)
1 |
2,878
|
4,674
|
7,320
|
6,749
|
9,302
|
11,709
|
11,457
|
11,124
|
P/E ratio
|
31.5
x
|
36.3
x
|
45.2
x
|
29.2
x
|
34.5
x
|
35.8
x
|
30.6
x
|
26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.5
x
|
5.35
x
|
6.81
x
|
4.51
x
|
4.99
x
|
5.71
x
|
4.92
x
|
4.27
x
|
EV / Revenue
|
3.34
x
|
5.05
x
|
6.41
x
|
4.62
x
|
4.93
x
|
5.39
x
|
4.54
x
|
3.83
x
|
EV / EBITDA
|
19.2
x
|
24.9
x
|
32.8
x
|
21.9
x
|
25.7
x
|
27.1
x
|
22.6
x
|
18.7
x
|
EV / FCF
|
15.6
x
|
20.6
x
|
31.1
x
|
19.2
x
|
23.4
x
|
26.8
x
|
23.2
x
|
19.8
x
|
FCF Yield
|
6.39%
|
4.86%
|
3.21%
|
5.2%
|
4.26%
|
3.74%
|
4.32%
|
5.05%
|
Price to Book
|
4.35
x
|
6.51
x
|
8.61
x
|
18.5
x
|
17.5
x
|
13.2
x
|
10.2
x
|
7.9
x
|
Nbr of stocks (in thousands)
|
35,812
|
35,572
|
35,754
|
31,018
|
30,683
|
30,913
|
-
|
-
|
Reference price
2 |
84.06
|
139.2
|
217.6
|
212.4
|
306.5
|
401.2
|
401.2
|
401.2
|
Announcement Date
|
2/24/20
|
2/15/21
|
2/14/22
|
2/13/23
|
2/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
861
|
925.9
|
1,142
|
1,460
|
1,886
|
2,170
|
2,522
|
2,906
|
EBITDA
1 |
149.6
|
187.8
|
223.1
|
308.1
|
362.5
|
431.4
|
506.6
|
593.9
|
EBIT
1 |
141.2
|
176.1
|
207.1
|
285.8
|
338.4
|
401.2
|
473.3
|
557.9
|
Operating Margin
|
16.4%
|
19.02%
|
18.13%
|
19.57%
|
17.94%
|
18.48%
|
18.77%
|
19.2%
|
Earnings before Tax (EBT)
1 |
124.8
|
168.5
|
201.9
|
282.9
|
335.7
|
425.7
|
502.7
|
587.8
|
Net income
1 |
100.4
|
145.4
|
181.8
|
245.4
|
282.8
|
359.6
|
420.7
|
493.1
|
Net margin
|
11.67%
|
15.7%
|
15.92%
|
16.81%
|
15%
|
16.57%
|
16.68%
|
16.97%
|
EPS
2 |
2.670
|
3.840
|
4.810
|
7.280
|
8.880
|
11.22
|
13.11
|
15.46
|
Free Cash Flow
1 |
184
|
227.3
|
235.1
|
351.2
|
396.7
|
437.7
|
494.5
|
561.4
|
FCF margin
|
21.37%
|
24.55%
|
20.58%
|
24.05%
|
21.04%
|
20.17%
|
19.61%
|
19.32%
|
FCF Conversion (EBITDA)
|
122.97%
|
121.08%
|
105.37%
|
113.98%
|
109.44%
|
101.45%
|
97.61%
|
94.54%
|
FCF Conversion (Net income)
|
183.14%
|
156.37%
|
129.26%
|
143.12%
|
140.28%
|
121.72%
|
117.53%
|
113.85%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/15/21
|
2/14/22
|
2/13/23
|
2/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
308.6
|
330.9
|
351.2
|
383.7
|
394.1
|
434.1
|
460.9
|
492.5
|
498.4
|
511
|
528.7
|
556.3
|
572.8
|
594
|
619.9
|
EBITDA
1 |
61.41
|
70.38
|
68.09
|
89.26
|
80.37
|
92.85
|
83.63
|
90.18
|
95.84
|
115.7
|
100.3
|
106.2
|
110.4
|
126.2
|
119.4
|
EBIT
1 |
57.22
|
66.11
|
63.38
|
84.31
|
74.47
|
87.44
|
77.66
|
83.86
|
89.41
|
109
|
93.95
|
100.2
|
103.8
|
116.3
|
111.8
|
Operating Margin
|
18.55%
|
19.98%
|
18.05%
|
21.97%
|
18.9%
|
20.14%
|
16.85%
|
17.03%
|
17.94%
|
21.33%
|
17.77%
|
18.01%
|
18.12%
|
19.58%
|
18.04%
|
Earnings before Tax (EBT)
1 |
55.92
|
65.32
|
62
|
81.89
|
73.64
|
86.03
|
75.74
|
83.2
|
90.71
|
112.8
|
98.45
|
105.3
|
109.9
|
123.6
|
117.7
|
Net income
1 |
50.03
|
61.31
|
49.36
|
66.03
|
68.67
|
72.89
|
61.07
|
70.55
|
78.3
|
102.6
|
81.08
|
86.76
|
90.5
|
103.5
|
98.55
|
Net margin
|
16.22%
|
18.53%
|
14.05%
|
17.21%
|
17.42%
|
16.79%
|
13.25%
|
14.32%
|
15.71%
|
20.07%
|
15.34%
|
15.6%
|
15.8%
|
17.42%
|
15.9%
|
EPS
2 |
1.320
|
1.690
|
1.460
|
2.050
|
2.120
|
2.270
|
1.930
|
2.220
|
2.460
|
3.200
|
2.518
|
2.706
|
2.812
|
3.253
|
3.075
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/22
|
4/25/22
|
7/25/22
|
10/24/22
|
2/13/23
|
4/24/23
|
7/24/23
|
10/23/23
|
2/12/24
|
4/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
161
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
132
|
278
|
461
|
-
|
103
|
693
|
946
|
1,278
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.5213
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
184
|
227
|
235
|
351
|
397
|
438
|
495
|
561
|
ROE (net income / shareholders' equity)
|
17.2%
|
19.9%
|
20.7%
|
36.6%
|
59.8%
|
45.7%
|
37.4%
|
35.8%
|
ROA (Net income/ Total Assets)
|
10.7%
|
-
|
11.9%
|
16.3%
|
18.8%
|
18.2%
|
16.6%
|
15.6%
|
Assets
1 |
935.7
|
-
|
1,525
|
1,506
|
1,505
|
1,974
|
2,528
|
3,152
|
Book Value Per Share
2 |
19.30
|
21.40
|
25.30
|
11.50
|
17.60
|
30.40
|
39.40
|
50.80
|
Cash Flow per Share
2 |
5.370
|
6.860
|
6.990
|
11.50
|
13.60
|
16.20
|
14.90
|
16.80
|
Capex
1 |
17.9
|
31.3
|
28.3
|
36.9
|
36.6
|
41.3
|
46.7
|
48.4
|
Capex / Sales
|
2.08%
|
3.38%
|
2.47%
|
2.53%
|
1.94%
|
1.9%
|
1.85%
|
1.67%
|
Announcement Date
|
2/24/20
|
2/15/21
|
2/14/22
|
2/13/23
|
2/12/24
|
-
|
-
|
-
|
Last Close Price
401.2
USD Average target price
428.2
USD Spread / Average Target +6.74% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.88% | 12.4B | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +0.61% | 12.23B | | +25.06% | 12.2B | | -9.14% | 11.06B |
Other Biotechnology & Medical Research
|